Quantcast
Last updated on April 16, 2014 at 11:09 EDT

Latest Proinflammatory cytokine Stories

2012-07-25 13:56:17

In a study published June 25 in the Journal of Neuroscience, a collaborative team of researchers led by Linda J. Van Eldik, director of the University of Kentucky Sanders-Brown Center on Aging, and D. Martin Watterson of the Northwestern University Feinberg School of Medicine, present results showing that a new central nervous system drug compound can reduce Alzheimer's pathology in a mouse model of the disease. The drug, called MW-151, is a selective suppressor of brain inflammation and...

2012-07-23 18:20:31

MELBOURNE, Australia, July 23, 2012 /PRNewswire/ -- Key Points: * Intravenous injection of Mesenchymal Precursor Cells (MPCs) resulted in selective migration to inflamed joints and lymph nodes in a sheep model of Rheumatoid Arthritis (RA) * A single intravenous injection of allogeneic, or "off-the-shelf", MPCs significantly reduced synovial tissue levels of TNF-alpha, IL-6, and IL-17, and reduced mononuclear cell infiltration * Reduced cytokine and inflammatory cell levels were...

2009-11-30 09:43:00

KING OF PRUSSIA, Pa., Nov. 30 /PRNewswire/ -- Cytokine PharmaSciences, Inc. today announced the completion of a Phase I study of CPSI-2364, its orally active, small-molecule inhibitor of the production of TNF-alpha and other pro-inflammatory cytokines. Results of the safety and tolerability dose escalation study in healthy volunteers confirm the safety of this compound in initial clinical testing. All 30 enrolled subjects completed the study, including those receiving the highest dose...

2009-11-14 08:42:16

Couples who bring thoughtful words to a fight release lower amounts of stress-related proteins, suggesting that rational communication between partners can ease the impact of marital conflict on the immune system. "Previous research has shown that couples who are hostile to each other show health impairments and are at greater risk of disease," said Jennifer Graham, assistant professor of biobehavioral health, Penn State. "We wanted to know if couples who use thoughtfulness and reasoning in...

2009-07-20 07:00:00

KING OF PRUSSIA, Pa., July 20 /PRNewswire/ -- Cytokine PharmaSciences, Inc. today announced the initiation of a Phase I study of CPSI-2364, its orally active, small-molecule inhibitor of the production of TNF-alpha and other pro-inflammatory cytokines. Results of the dose escalation and safety study in healthy volunteers are expected before the end of the year. "Based on extensive work with the predecessor compound, we believe CPSI-2364 has the potential to revolutionize the treatment of...